Medical/Pharmaceuticals
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate can...
/C O R R E C T I O N -- Seegene Inc./
In the news release, "Seegene Establishes French Subsidiary to Expand European Footprint", issued05-Dec-2025 by Seegene Inc. over PR Newswire, we are advised by the company that the first sub-headline should read "France becomes Seegene's eighth overseas sales subsidiary and third inEurope, follo...
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer
- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts g...
Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation
Collaboration aimed at accelerating R&D in both small- and large-molecule
analysis and building high-impact capabilities in fast-growing Asian markets
KUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc.
Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)
Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of ...
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR...
Menarini Asia-Pacific Expands Production Facilities, Strengthening Indonesia's Role as Regional Manufacturing Hub
* Menarini announces the expansion of MiLab facilities in Cikarang, including a new warehouse andenhanced production facility to meet growing export demands. * Another milestone includes the projected export of up to 700,000 units of Dermatix products toChina alone this year. * The event hig...
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of annualAsia-Pacific meeting in Singapore SINGAPORE, Dec. 4, 2025 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) today launched its call for abstracts for i...
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug
development and operational excellence to propel Emerald's continued growth.
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- Emerald
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong . These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lym...
S3 Connected Health Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity
Recognized for pioneering advancements that redefine medical device
connectivity, accelerate home-based care, and deliver transformative value
across global healthcare ecosystems.
SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ -- Frost & Sullivan
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- MediThinQ
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIOUSLY SHOWN TO IMPROVE COGNITION -- MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary
studies -
Key Takeaways
* Findings from three NIA-funded ancillary studies to the U.S. POINTER trial
TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact
Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose Summary TraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the U.S.,India, and Spain and providing volunteer opp...
Frost & Sullivan: Health Recovery Solutions Receives the 2025 North American Customer Value Leadership Recognition for Excellence in Patient-Centered Care Delivery
Frost & Sullivan recognizes Health Recovery Solutions for delivering adaptable,
outcomes-driven, technology-enabled longitudinal care models
SAN ANTONIO, Dec. 2, 2025 /PRNewswire/ -- Frost & Sullivan
Neusoft Medical Systems Unveils World's First 8cm Wide-Coverage Photon-Counting CT and Other Premium Innovations at RSNA 2025
CHICAGO, Dec. 2, 2025 /PRNewswire/ -- Neusoft Medical Systems Co., Ltd. ("Neusoft Medical"), a global leader in medical imaging, is showcasing its comprehensive portfolio of intelligent healthcare innovations at the Radiological Society ofNorth America (RSNA) 2025 annual meeting. The highlight o...
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to...
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement
HSINCHU, Dec. 2, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvantAB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FD...
Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers Detection
BANGKOK, Dec. 2, 2025 /PRNewswire/ -- The Faculty of Medicine
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:0901F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 273 media titles]
2026-09-21 08:00Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51